Tasly

Transgene Reports Business Update and Q3 2023 Financial Position

Retrieved on: 
Tuesday, November 7, 2023

Revenue from collaborative and licensing agreements amounted to €1.2 million in the first nine months of 2023, compared with €3 million in the same period in 2022.

Key Points: 
  • Revenue from collaborative and licensing agreements amounted to €1.2 million in the first nine months of 2023, compared with €3 million in the same period in 2022.
  • In the first half of 2023, AstraZeneca informed Transgene of its decision to end the collaboration.
  • Cash, cash equivalents and other financial assets stood at €16.4 million as of September 30, 2023, compared to €26.8 million as of December 31, 2022.
  • On September 20, 2023, the Company signed a current account advance agreement with Institut Mérieux (TSGH) for a maximum of €36 million.

Yoshitsu Co., Ltd Announces Strategic Cooperation with Tasly Holding Group Co., Ltd

Retrieved on: 
Friday, October 27, 2023

Yoshitsu expects this collaboration with Tasly to help solidify and grow Yoshitsu’s presence in the health product sector.

Key Points: 
  • Yoshitsu expects this collaboration with Tasly to help solidify and grow Yoshitsu’s presence in the health product sector.
  • Yoshitsu and Tasly also plan to assist each other with the registration and approval procedures necessary for health products to be sold in Japan, mainland China, Hong Kong, Macau, and other overseas markets.
  • Yoshitsu and Tasly aim to utilize their respective sales networks and logistics distribution systems to help each other improve their respective supply chain systems and distribution channels in international markets.
  • Mr. Mei Kanayama, the Principal Executive Officer of Yoshitsu Co., Ltd, commented, “We believe that this alliance with Tasly demonstrates our commitment to grow our presence in the health product sector.

Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products

Retrieved on: 
Thursday, September 28, 2023

Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. (" Triastek ") today announced the completion of a USD 20.4 million Pre-C financing round.

Key Points: 
  • Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. (" Triastek ") today announced the completion of a USD 20.4 million Pre-C financing round.
  • Triastek’s proprietary technology, the Melt Extrusion Deposition (MED®) 3D printing process, combined with digital formulation development methods, enables complex drug delivery and programmed release.
  • Triastek, as a leading provider of digital pharmaceutical process technology, is continuously advancing applications of 3D printing technology to produce novel pharmaceutical products that improve patient outcomes.
  • The company has engaged in extensive business collaborations with global pharmaceutical companies, focusing on novel products and advanced technical solutions.

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on: 
Thursday, March 30, 2023

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.

Key Points: 
  • The safety profile is generally consistent with prior data; asymptomatic neutropenia was the primary adverse event and no new safety signals were observed.
  • Additional Pipeline Programs: A Sutro Research Forum, held in 2022, highlighted STRO-003 and Sutro’s emerging research portfolio.
  • Sutro bolstered the Senior Management Team with the promotion of Brunilda Shtylla to Chief Business Officer, who leads Business Development.
  • Total operating expenses for the year ended December 31, 2022 were $196.7 million, as compared to $160.4 million for the same period in 2021.

Global Angina Pectoris Treatment Market Report 2022 to 2030 - Featuring Forest Laboratories, Gilead Sciences, GlaxoSmithKline, Novartis and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023

Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.

Key Points: 
  • Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.
  • The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2030.
  • What are the key micro and macro environmental factors that are impacting the growth of Angina Pectoris Treatment market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Angina Pectoris Treatment market worldwide?

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

Retrieved on: 
Monday, August 8, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the quarter ended June 30, 2022, its recent business highlights, and a preview of anticipated select milestones.

Key Points: 
  • Sutro expects to report additional data on efficacy, safety, and durability from the dose-expansion cohort, together with the design of a potential registrational study, in the second half of 2022.
  • As of June 30, 2022, Sutro held approximately 1.6 million shares of Vaxcyte common stock, with a fair value of $34.0 million.
  • Total operating expenses for the quarter ended June 30, 2022 were $47.5 million, as compared to $37.9 million for the same period in 2021.
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors

Retrieved on: 
Monday, June 20, 2022

Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors

Key Points: 
  • Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
    PARIS, France, June 20, 2022, 08:30 am CET Pharnext SA (FR0011191287 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces that at its Annual General Meeting (AGM) on Friday June 17th all key resolutions proposed by the Pharnext Board of Directors (the "Board") were adopted.
  • On June 16, 2022, the Board co-opted Dr. James Kuo to replace Mr. Alex Berda, who resigned from the Board earlier this month.
  • Ratification of Dr. James Kuos Board membership will be submitted for approval at the next Shareholders meeting of the Company.

Transgene: Q1 2022 Financial Position and Business Update

Retrieved on: 
Tuesday, May 10, 2022

During the first quarter of 2022, revenue from collaborative and licensing agreements was mainly composed of revenue from the collaboration with AstraZeneca.

Key Points: 
  • During the first quarter of 2022, revenue from collaborative and licensing agreements was mainly composed of revenue from the collaboration with AstraZeneca.
  • Cash, cash equivalents and other financial assets stood at 46.8 million as of March 31, 2022, compared to 49.6 million as of December 31, 2021.
  • In the first quarter of 2022, Transgenes net cash burn was 2.8 million, compared to 7.2 million for the same period in 2021.
  • The Company holds shares of Tasly BioPharmaceuticals valued at 18.9 million at the end of December 2021.

Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022

Retrieved on: 
Wednesday, March 16, 2022

These results demonstrated the immunogenicity of the vaccine, which led to the first signs of clinical activity.

Key Points: 
  • These results demonstrated the immunogenicity of the vaccine, which led to the first signs of clinical activity.
  • We expect to confirm these results in the coming months and to provide more in-depth data at major scientific congresses in 2022.
  • First data from an interim analysis, including up to 50 patients, is anticipated in the fourth quarter of 2022.
  • Transgene expects to report the results of this analysis in the fourth quarter of 2022.

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

Retrieved on: 
Monday, December 27, 2021

Sutro retains development and commercial rights of STRO-002 outside of Greater China.

Key Points: 
  • Sutro retains development and commercial rights of STRO-002 outside of Greater China.
  • Upon commercialization, Sutro will receive tiered, double-digit royalties based on annual net sales of STRO-002 in Greater China.
  • Tasly is an excellent partner for our Greater China collaboration, with a history of successful execution for developing and commercializing therapeutics.
  • As a leading innovative biopharmaceutical company in China, Tasly Biopharmaceuticals has a commercialization platform integrating research and development, manufacturing and sales.